13th Tumor Models Summit Boston | July 22-23, 2025 | Boston, MA
Tuesday, July 22, 2025 -- Wednesday, July 23, 2025, 0800 - 1605
Welcome to the 13th Tumor Models Summit Boston: The East Coast Tumor Modeling Industry's Leading Networking and Innovation Opportunity
The tumor modeling industry is abuzz, with Merck's acquisition of HUB organoids, Takeda's expanded collaboration with Tempus to utilize biologically relevant models, and the FDA Modernization Act 3.0 promoting reduced animal use. Yet, with cancer drugs translating to the clinic at only ~5% and clinical trial failure rates rising, the need to invest in more predictive models to de-risk candidate development has never been greater.
Built by biopharma, for biopharma, the 13th Tumor Models Summit Boston returns to bring together 180+ East Coast tumor modeling experts from pharma, biotech, and preclinical CROs, to enable you to stay abreast of confidently implementing reproducible and predictive oncology models to successfully bridge the translational gap with optimized efficiency, and cost-effectiveness.
URLs:
Brochure: https://go.evvnt.com/3017844-0?pid=2874
Website: https://go.evvnt.com/3017844-1?pid=2874
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Prices:
Service and Solution Provider - Conference Only: USD 3699.00,
Drug Developers - Conference Only: USD 0.50
Speakers: Abha Dhaneshwar, Senior Scientist - Research Oncology, Takeda, Amy Daniel-Ulumben, Senior Associate Scientist, Compass Therapeutics, Andrew Price, Senior Principal Scientist, Novartis, Colles Price, Scientific Associate Director, Takeda, Domenico Bullara, Quantitative Systems Pharmacologist, Novartis, Durga Dandamudi, Senior Scientist II, Translational Oncology, Abbvie, Elisa Mandato, Instructor, Dana-Farber Cancer Institute, Hongyu Xue, Director - In Vivo Pharmacology, Oncology and Research, Bayer, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Katarina Halpin-Veszeleiova, Senior Scientist - In Vivo Pharmacology Research, KSQ Therapeutics, Laura Kazlauskas, Senior Scientist, AstraZeneca, Liam Jenkins, Associate Director, AstraZeneca, Lochana Seenappa, Scientist - Translational Imaging, Merck and Co, Marco Campisi, Postdoctoral Research Fellow, Dana-Farber Cancer Center, Meghana Pandya, Senior Scientist, AstraZeneca, Robert Getzenberg, Director, Medical Affairs, Companion Diagnostics Oncology, Astellas, Rosa Ng, Associate Director, Takeda, Sadhak Sengupta, Senior Director, Research and Development, IN8Bio, Sarah O'Brien, Senior Principal Scientist, Cancer Immunology, Immune Modulation, Boehringer Ingelheim, Shahin Rafii, Professor, Weill Cornell Medical College, Sunanda Singh, Founder and Chief Executive Officer, Singh Biotechnology LLC, Thomas Baumert, Founder, Alentis Therapeutics, Zohreh Amoozgar, Principal Scientist and Head of Lab, Sanofi
The tumor modeling industry is abuzz, with Merck's acquisition of HUB organoids, Takeda's expanded collaboration with Tempus to utilize biologically relevant models, and the FDA Modernization Act 3.0 promoting reduced animal use. Yet, with cancer drugs translating to the clinic at only ~5% and clinical trial failure rates rising, the need to invest in more predictive models to de-risk candidate development has never been greater.
Built by biopharma, for biopharma, the 13th Tumor Models Summit Boston returns to bring together 180+ East Coast tumor modeling experts from pharma, biotech, and preclinical CROs, to enable you to stay abreast of confidently implementing reproducible and predictive oncology models to successfully bridge the translational gap with optimized efficiency, and cost-effectiveness.
URLs:
Brochure: https://go.evvnt.com/3017844-0?pid=2874
Website: https://go.evvnt.com/3017844-1?pid=2874
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Prices:
Service and Solution Provider - Conference Only: USD 3699.00,
Drug Developers - Conference Only: USD 0.50
Speakers: Abha Dhaneshwar, Senior Scientist - Research Oncology, Takeda, Amy Daniel-Ulumben, Senior Associate Scientist, Compass Therapeutics, Andrew Price, Senior Principal Scientist, Novartis, Colles Price, Scientific Associate Director, Takeda, Domenico Bullara, Quantitative Systems Pharmacologist, Novartis, Durga Dandamudi, Senior Scientist II, Translational Oncology, Abbvie, Elisa Mandato, Instructor, Dana-Farber Cancer Institute, Hongyu Xue, Director - In Vivo Pharmacology, Oncology and Research, Bayer, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Katarina Halpin-Veszeleiova, Senior Scientist - In Vivo Pharmacology Research, KSQ Therapeutics, Laura Kazlauskas, Senior Scientist, AstraZeneca, Liam Jenkins, Associate Director, AstraZeneca, Lochana Seenappa, Scientist - Translational Imaging, Merck and Co, Marco Campisi, Postdoctoral Research Fellow, Dana-Farber Cancer Center, Meghana Pandya, Senior Scientist, AstraZeneca, Robert Getzenberg, Director, Medical Affairs, Companion Diagnostics Oncology, Astellas, Rosa Ng, Associate Director, Takeda, Sadhak Sengupta, Senior Director, Research and Development, IN8Bio, Sarah O'Brien, Senior Principal Scientist, Cancer Immunology, Immune Modulation, Boehringer Ingelheim, Shahin Rafii, Professor, Weill Cornell Medical College, Sunanda Singh, Founder and Chief Executive Officer, Singh Biotechnology LLC, Thomas Baumert, Founder, Alentis Therapeutics, Zohreh Amoozgar, Principal Scientist and Head of Lab, Sanofi
Starting Price Per Person
$ 0.50 USD
Other Information
Where
The Westin Boston Seaport District
425 Summer Street
Boston Massachusetts 02210
United States
( Hotel - Resort )
425 Summer Street
Boston Massachusetts 02210
United States
( Hotel - Resort )
Event Organizer Contact
More Events
Event ID: 250893
Get Events in Your Inbox
We have over 100,000 Events in 80+ Categories. Tell us what type of events you like, and we will send them to your inbox